5 Result(s)
within
C Benson
Biomedicine, general
Cancer Research
Drug Resistance
-
Article
Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
Since the publication of this paper, the authors noticed an error in Fig. 1. The X-axis on all the figure panels should read ‘Time (years)’, not ‘Time (months)’. The corrected Fig. 1 is shown below.
-
Article
Open AccessChemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in contemporary oncology practice. In a pilot study of radiation-ind...
-
Article
Open AccessA phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broa...
-
Article
Open AccessClinical anticancer drug development: targeting the cyclin-dependent kinases
Cell division involves a cyclical biochemical process composed of several step-wise reactions that have to occur once per cell cycle. Dysregulation of cell division is a hallmark of all cancers. Genetic and ep...
-
Article
Open AccessThe treatment of advanced renal cell cancer with high-dose oral thalidomide
Thalidomide is reported to suppress levels of several cytokines, angiogenic and growth factors including TNF-α, basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukin-...
